We are advancing a pipeline of novel therapeutics for epilepsies, autism, and other CNS disorders.

science

Pushing the boundaries of neuroscience drug discovery


We couple emerging advances in neuroscience drug discovery and precision medicine for neuroscience to advance our pipeline of small molecule therapies for CNS disorders. Our therapies are designed to selectively inhibit clinically validated therapeutic targets and restore neuronal balance.

 

team

Working at IAMA therapeutics



We are a team of scientists, researchers, and biotech industry experts who value excellence, innovation, integrity, equality, respect for diversity, and the sustainability of our future generations.

latest news

19 February 2024

IAMA Therapeutics Successfully Dosed the First Two Cohorts in First-in-Human Clinical Trial

GENOA, Italy, February 19, 2024 — IAMA Therapeutics has successfully dosed the first two cohorts of subjects and has started dosing the third one in the […]
23 January 2024

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
20 December 2023

IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy, December 20, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]